Upcoming events – Beacons of hope for Array and Proteon
Array Biopharma hopes for a label extension for its Braf/Mek inhibitor, and Proteon tries to make a better fist of its second phase III trial of vonapanitase.
In sticking to the knitting has Array given up too much?
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
